RR Research

In China, the medical organizations refer to the organizations received Practice License of Medical Institution, mainly including the specialized diagnostic and curative hospitals, health centers, convalescent hospitals, out-patient clinics, clinics, hygiene centers and first-aid stations etc.   The medical organizations in China belong to service industry, directly faced to numerous consumers and supervised by medical executive departments of Chinese government. The regional distributions of Chinese hygiene resources are comparatively balanced, regional distribution disparity mainly showing in the levels of medical organizations, asset scales, revenues and expenditures, private medical organization distribution and foreign funded medical distribution, reflecting the regional economic development differences. Chinese medical industry is mainly concentrated in Shanghai, Beijing, Guangdong and Zhejiang, accounting for most hygiene resources and higher level technologies.   In 2008, the total expenditures of Chinese medical industry were 1.22 trillion Yuan (174 billion USD), increasing by 8.2% of last year. The expenditures per capita were 915 Yuan (130 USD).      By the end of 2008, Chinese health organizations were about 300 thousand, in which hospitals were 19,701 (13,111 public hospitals), 40 thousand clinics, 28 thousand community health service centers, 3,020 maternity .. more»

The big-pharma companies are increasingly outsourcing their production of drugs to contract manufacturing organizations (CMOs) solely to reduce cost of production, working capital requirement, and time-to-market, or to obtain a specific expertise not available in-house. The biggest factor to drive the growth of CMOs in the pharmaceutical industry is the growing need of state-of-the-art process & production technologies, which have proven highly effective in meeting regulatory requirements.The global market for bio-pharma has grown at a CAGR of 11.2% over the last few years. The share of the CMO market of the total bio-pharma market has also increased over 2001 to -2008. The Bio-Pharma CMO market can be segmented into Mammalian CMO market and Microbial CMO market. The largest capacity share of the bio-pharma CMO market is held by the Mammalian CMO market. The main growth driver of the bio-pharma CMO market is the increasing outsourcing trend among the bio-pharma manufacturers as a result of stringent regulatory environment. However, factors like global economic crisis, intellectual property risk, increasing regulatory cost, and lack of integrated CMOs are also acting as a roadblock in the path of overall industry growth, .. more»